|Bid||55.66 x 1000|
|Ask||55.70 x 900|
|Day's Range||54.90 - 56.50|
|52 Week Range||24.58 - 66.76|
|Beta (3Y Monthly)||N/A|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||41.75|
Shockwave Medical, Inc. (SWAV), a pioneer in the development and commercialization of Intravascular Lithotripsy (IVL) to treat complex calcified cardiovascular disease, announced today that the Company has appointed Keith D. Dawkins, M.D. as Chief Medical Officer. “Given the challenges associated with treating calcium throughout the cardiovascular system, joining Shockwave and contributing to the development of what will likely become the new standard of care for calcium modification was an attractive opportunity,” said Dr. Dawkins.
The medical device maker's first earnings report as a public company featured explosive revenue growth and upbeat full-year guidance.
A South San Francisco biotech's offering soared on Thursday, but a San Mateo ruggedized smartphone maker's priced well below its targets. Here's more on that and other Bay Area founder and funder news at the end of the week.
The Fremont, California-based company said it had a loss of $1.37 per share. The results fell short of Wall Street expectations. The average estimate of three analysts surveyed by Zacks Investment Research ...
SANTA CLARA, Calif., May 08, 2019 -- Shockwave Medical, Inc. (Nasdaq: SWAV), a pioneer in the development and commercialization of Intravascular Lithotripsy (IVL) to treat.
The measure of the health of the venture and startup world has dropped for two straight quarters now, down from 17-year highs by about 15 percent.
SANTA CLARA, Calif., May 01, 2019 -- Shockwave Medical, Inc. (Nasdaq: SWAV), a pioneer in the development and commercialization of Intravascular Lithotripsy (IVL) to treat.
The company joins joins what could be a busy month for Bay Area IPOs in May, which is expected to include Uber's massive offering, Slack's direct listing and the market debut of South San Francisco biotech Cortexyme.
These three health and technology stocks are seeing technical strength ahead of upcoming earnings. Evolus, Inc. (NASDAQ: EOLS ) gained 50 cents to $26.44 on 537,100 shares Wednesday. The performance beauty ...
Evolus Inc. (EOLS) gained 50 cents to $26.44 on 537,100 shares traded Wednesday. The performance-beauty company said it will release earnings after the close of the stock market April 30. Extreme Networks Inc. (EXTR) rose 29 cents to $8.26 on 2.1 million shares traded Wednesday, nearly 1 1/2 times its average volume.
SANTA CLARA, Calif., April 24, 2019 -- Shockwave Medical, Inc. (Nasdaq: SWAV), a pioneer in the development and commercialization of Intravascular Lithotripsy (IVL) to treat.
The number of Bay Area exits via IPOs and M&A; in the first quarter dropped sharply to 40, according to PitchBook Data, less than half the total from last year's first quarter.
The Sunnyvale-based medical device business sold 6 million shares at $20 each instead of the 4.7 million shares it originally planned to sell for between $15 and $17 apiece.
Shockwave Medical, Inc. (SWAV), a pioneer in the development and commercialization of Intravascular Lithotripsy (IVL) to treat complex calcified cardiovascular disease, has completed enrollment of its DISRUPT CAD II study, a regulatory-required European post-market registry of coronary IVL. DISRUPT CAD II is a prospective, non-randomized, multicenter, real-world study to confirm the safety and performance results from the DISRUPT CAD I study, which was used to obtain European approval of the Shockwave Coronary IVL System.
ShockWave Medical, Inc. (“ShockWave”) (SWAV), today announced the closing of its initial public offering of 6,555,000 shares of its common stock at an initial public offering price of $17.00 per share, including 855,000 shares sold pursuant to the exercise in full of the underwriters’ option to purchase additional shares. ShockWave’s common stock is listed on the Nasdaq Global Select Market under the ticker symbol “SWAV”. Morgan Stanley and BofA Merrill Lynch acted as joint lead book-running managers for the offering.
"I feel like a kid in a candy store right now," CEO Doug Godshall told the Business Journal after his company's first day of trading on Wall Street. Here's what's next for Shockwave after its blockbuster debut on the Nasdaq.
Six fundings, six acquisition deals and another company getting set to go public highlight Bay Area venture news at the end of the week. Here's more of those and other founder and funder news from the region.